恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦(Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Alafenamide Fumarate)

概要

基本信息

药物类型

小分子化药

别名

Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Alafenamide、Emtricitabine/Rilpivirine/Tenofovir Alafenamide、Emtricitabine/rilpivirine/tenofovir alafenamide

+ [10]

靶点

RT

作用机制

RT抑制剂(逆转录酶抑制剂)

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症

HIV感染

非在研适应症-

原研机构

Gilead Sciences, Inc.

在研机构

Gilead Sciences, Inc.

Janssen Global Services LLCGilead Sciences Ireland UC

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2016-03-01),

HIV感染

最高研发阶段(中国)-

特殊审评优先审评 (美国)

登录后查看时间轴

结构

分子式C8H10FN3O3S

InChIKeyXQSPYNMVSIKCOC-NTSWFWBYSA-N

CAS号143491-57-0

查看全部结构式(3)

关联

7

项与恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦相关的临床试验

PACTR202209528604242 / Suspended临床2期IIT

Safety and Pharmacokinetics of TAF-FTC Pre-Exposure Prophylaxis in Kenyan Cisgender women- of TDF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender women.

开始日期2022-06-01

申办/合作机构

University of Washington

CTR20220535 / CompletedN/A

恩曲他滨利匹韦林丙酚替诺褔韦片的人体生物等效性研究

主要研究目的：评估受试制剂恩曲他滨利匹韦林丙酚替诺褔韦片（规格：200mg/25mg/25mg，齐鲁制药有限公司生产）与参比制剂恩曲他滨利匹韦林丙酚替诺褔韦片（ODEFSEY®，规格：200mg/25mg/25mg，Gilead Sciences Inc生产）作用于空腹和餐后状态下健康成年受试者的生物等效性。次要研究目的：评估受试制剂恩曲他滨利匹韦林丙酚替诺褔韦片与参比制剂恩曲他滨利匹韦林丙酚替诺褔韦片（ODEFSEY®）在健康成年受试者中的安全性。

开始日期2022-04-07

申办/合作机构

齐鲁制药有限公司

NCT03092206 / Completed临床1期

Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication: The TAF-IR Study

Investigation of possible changes in insulin sensitivity in healthy volunteers taking the following HIV treatment combinations: F/TAF (group 1) as compared to E/C/F/TAF (group 2) as compared to R/F/TAF (group 3). The measurement of insulin sensitivity will be performed in 30 HIV-negative healthy non-obese (BMI 18-25) male volunteers before and after 14±2 days of treatment. The volunteers will be randomly assigned to one of the three groups. Changes in insulin sensitivity will be measured by golden standard hyperinsulinemic euglycemic clamp (HEGC) technique, using glucose and insulin infusion as diagnostic agents

开始日期2017-04-18

申办/合作机构

Technische Universität München

100 项与恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦相关的临床结果

登录后查看更多信息

100 项与恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦相关的转化医学

登录后查看更多信息

100 项与恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦相关的专利（医药）

登录后查看更多信息

7

项与恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦相关的文献（医药）

2022-12-01·AIDS

Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide

Article

作者: Gabriel, Nico ; Hernandez, Inmaculada ; Dickson, Sean

We estimated list and net prices for tenofovir disoproxil fumarate (TDF) products Truvada, Complera, and Stribild, and their tenofovir alafenamide (TAF) versions Descovy, Odefsey, and Genvoya. Gilead offered discounts for Descovy that resulted into lower net prices compared to Truvada. This strategy encouraged patients switching from Truvada to Descovy before the availability of generic Truvada. Conversely, Gilead offered lower discounts for Odefsey and Genvoya, which resulted into higher net prices compared to Complera and Stribild.

2020-12-01·Acta Tropica3区 · 医学

Comparing PCR techniques against conventional cercarial shedding methods for detecting Schistosoma mansoni infection in Biomphalaria snails

3区 · 医学

Article

作者: Joof, Ebrima ; Sowunmi, Kehinde ; Onyango, Victor M ; Wade, Christopher M ; Andrus, Peter S

The detection of Schistosoma mansoni infection in both its intermediate (snail) and definitive (human) hosts is useful in providing information on the transmission of schistosomiasis. Three pairs of previously designed PCR primers (SM^1-7, SM^F/R & ND5) used for the detection of S. mansoni infection were tested. We assess the utility of each of these primer sets for detecting S. mansoni infection both in artificially exposed laboratory bred Biomphalaria glabrata, and field infected African Biomphalaria sudanica and Biomphalaria pfeifferi. Two of the three primer sets (SM^F/R & ND5) detected S. mansoni infection in snails, but amplification of S. mansoni DNA with SM^1-7 was unreliable. For the artificially exposed laboratory bred B. glabrata snails, SM^F/R and ND5 both detected infection in more snails than the cercarial shedding method. Infection detection rates were 62.4% for ND5, 57.1% for SM^F/R and 50.4% using traditional cercarial shedding methods. Both SM^F/R and ND5 detected S. mansoni infection in 91% of snails observed shedding cercariae, increasing to 98.5% when low stringency PCR methods were used. When comparing each of the detection methods using a Bayesian latent class analysis model, ND5 had the highest detection sensitivity and negative predictive value (NPV), while SM^F/R had the highest detection specificity and positive predictive value (PPV). In field collected Biomphalaria snails, ND5 detected S. mansoni infection in 21 of 24 snails categorised as shedding S. mansoni cercariae and 4 of 24 snails categorised as shedding non-S. mansoni cercariae, while SM^F/R detected infection in 18 of 24 snails categorised as shedding S. mansoni cercariae and in 3 of 24 snails categorised as shedding non-S. mansoni cercariae. All SM^F/R and ND5 PCR products were shown to be S. mansoni indicating that these field snails must have been infected with both S. mansoni and cercariae from other Schistosoma species. This indicates that the two primer sets are specific for S. mansoni and will not amplify non-S. mansoni species when used at their recommended annealing temperatures. Both the SM^F/R and ND5 primers effectively detected S. mansoni infection in three Biomphalaria species and have improved detection sensitivity over cercarial shedding.

2020-11-01·Journal of Virus Eradication4区 · 医学

Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting

4区 · 医学

Article

作者: DeJesus, Edwin ; Hinestrosa, Federico ; Rolle, Charlotte-Paige ; Nguyen, Vu

BACKGROUNDMulti-tablet regimens (MTRs) are associated with increased adverse events and non-adherence. Single tablet regimens (STRs) plus boosted protease inhibitors (PIs) are a simplification option for MTR-treated patients; however, data is needed to validate this therapeutic strategy.METHODSThis retrospective analysis included all HIV-1 infected patients seen at a single center from March 2016 to December 2017 who were switched from twice-daily (BID) regimens or regimens containing ≥ 3 pills daily to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (E/C/F/TAF) plus darunavir (DRV) or rilpivirine/emtricitabine/tenofovir-alafenamide (RPV/F/TAF) plus DRV boosted with ritonavir or cobicistat (DRV/r-c). Eligible patients had baseline HIV-1 RNA<200 copies/mL and were followed for 48 weeks. The primary endpoint was HIV-1 RNA≥50 copies/mL at Week 48. Adherence and safety data were recorded throughout the study.RESULTSOf 61 patients included, median age was 53 years, the median number of pills taken daily (range) was 5 (3-9), 80% were taking BID regimens, 97% had baseline HIV-1 RNA<50 copies/mL, 56 (92%) were switched to E/C/F/TAF plus DRV and 5 (8%) to RPV/F/TAF plus DRV/r-c. At Week 48, 2 patients (3%) had HIV-1 RNA≥ 50 copies/mL, both were treated with E/C/F/TAF plus DRV and neither had evidence of treatment-emergent resistance. Fifty-nine (97%) had an HIV-1 RNA<50 copies/mL. Adverse drug reactions (ADRs) occurred in 3/61 (5%) (all Grade 2) leading to 3/61 (5%) ADR-related discontinuations.CONCLUSIONIn this real-world cohort of MTR-treated patients, switching to a TAF-based STR plus boosted PI maintained virologic control in 97% and was well-tolerated, supporting potential use of this strategy for regimen simplification.

36

项与恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦相关的新闻（医药）

2024-10-09

·药融云

$9亿+肺动脉高压药，齐鲁制药拿下首仿！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 10月8日，据NMPA官网最新公示，齐鲁制药申报的利奥西呱片获批上市并视同通过一致性评价，该产品为首家获批上市。针对利奥西呱，默沙东与拜耳已战略合作推广，2023年全球销售额超9亿美元。截图来源：NMPA官网利奥西呱原研是拜耳/默沙东联合开发的一款可溶性鸟苷酸环化酶（sGC）激动剂，适应症为用于治疗慢性血栓栓塞性肺动脉高压（CTEPH）和动脉肺动脉高压（PAH）。2013年获FDA批准上市，用于慢性血栓栓塞性肺动脉高压和肺动脉高压。据药融云数据库显示，利奥西呱在2023年全球的销售额超9亿美元。利奥西呱片在2023年全国院内的销售额超6千万，同比增长达33.37%。截图来源：摩熵医药（原药融云）全国医院销售数据库利奥西呱于2017年9月进入中国市场，目前已经通过谈判进入了医保乙类目录。2023年医保目录仅含7款肺动脉高压靶向药，利奥西呱为其中之一。据药融云数据库显示，此前，利奥西呱片在国内市场上只有原研上市销售。此次齐鲁药业顺利获批，拿下国内首仿+首家过评。截图来源：摩熵医药（原药融云）过评药品汇总数据库利奥西呱在中国的化合物专利已于2023年在中国到期，据药融云数据库显示，利奥西呱片目前有宁波美诺华天康药业、江苏华阳制药2家药企提交了4类仿制药报产。截图来源：摩熵医药（原药融云）中国药品审评数据库 2024年至今，齐鲁制药(含子公司）有37个品种过评，其中利奥西呱片、卡维地洛片、二甲双胍恩格列净片(Ⅵ)、头孢泊肟酯片、恩曲他滨利匹韦林丙酚替诺福韦片等9个品种为首家过评。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，了解更多品牌升级详情！

上市批准一致性评价专利到期

2024-09-11

·微信

【关注】齐鲁拿下暴涨990%降脂药

精彩内容日前，国家药监局官网显示，齐鲁制药申报的4类仿制药ω-3脂肪酸乙酯90软胶囊获批生产并视同过评，为国产第4家。这是一款口服降脂药，2023年在中国三大终端六大市场（统计范围详见本文末）的销售额增速超过990%。 ω-3脂肪酸乙酯90软胶囊主要成分为二十碳五烯酸乙酯(EPA)与二十二碳六烯酸乙酯(DHA)，可减少甘油三酯在肝脏中的合成，适用于在控制饮食的基础上，降低重度高甘油三酯血症（≥500mg/dL）成年患者的甘油三酯(TG)水平。原研厂家的ω-3脂肪酸乙酯90软胶囊于2022年4月获批进入国内市场。米内网数据显示，近年来该产品在中国三大终端六大市场迅速放量，2023年销售额增速超过990%。 2022-2023年中国三大终端六大市场ω-3脂肪酸乙酯90软胶囊销售情况（单位：万元）来源：米内网格局数据库仿制药申报方面，目前已有四川国为制药、成都盛迪医药、人福普克药业、齐鲁制药4家企业的ω-3脂肪酸乙酯90软胶囊获批生产并视同过评；扬子江药业、北京双鹭药业、温州海鹤药业、江苏万高药业、浙江医药新昌制药等企业的产品报产在审。米内网数据显示，今年以来，齐鲁制药有29个品种获批生产并视同过评，其中，艾曲泊帕乙醇胺片、盐酸苯达莫司汀注射用浓溶液、氯苯唑酸葡胺软胶囊、二甲双胍恩格列净片(Ⅵ)、恩曲利匹丙诺片等为国内首仿。 2024年以来齐鲁制药获批上市的品种来源：米内网中国申报进度（MED）数据库此外，今年以来，齐鲁制药的1类新药伊鲁阿克片获批新适应症，雷珠单抗注射液、注射用曲妥珠单抗、地舒单抗注射液、注射用罗普司亭4款生物药获批上市，其中注射用罗普司亭为国产首家获批。资料来源：米内网数据库、国家药监局官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至9月11日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准

2024-09-05

·药融云

7亿+注射剂，齐鲁制药迎来过评！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 9月4日，据NMPA公示，齐鲁制药提交的达肝素钠注射液通过一致性评价。2024年至今，齐鲁制药（含子公司）有34款品种过评，其中有8款品种是首家过评。截图来源：NMPA官网达肝素钠注射液是一种抗凝血药，用于治疗急性深静脉血栓和不稳定型冠状动脉疾病如不稳定型心绞痛和非Q波型心肌梗死，也用于预防急性肾功能衰竭或慢性肾功能不全者进行血液透析和血液过滤期间体外循环系统中的凝血以及与手术相关的血栓形成。据药融云数据库显示，达肝素钠注射液在2023年全国院内市场的销售额超7亿元。截图来源：药融云全国医院销售数据库目前，达肝素钠注射液在国内有6家企业拥有生产批文，其中有河北常山生化药业、南京健友生化制药、常州千红生化制药、烟台东诚北方制药、齐鲁制药5家药企过评。截图来源：药融云中国药品审评数据库在仿制药布局方面，目前，达肝素钠注射液有辰欣药业提交了4类仿制申请上市。截图来源：药融云中国药品审评数据库 2024年至今，齐鲁制药（含子公司）有34款品种过评，其中有卡维地洛片、二甲双胍恩格列净片(Ⅵ)、头孢泊肟酯片、恩曲他滨利匹韦林丙酚替诺福韦片等8款品种是首家过评。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

一致性评价医药出海

100 项与恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J05AR19	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
HIV感染	美国	Gilead Sciences, Inc.	2016-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IAS2022	N/A	HIV感染	421	B/F/TAF	壓鏇選壓簾鑰糧衊蓋鏇(窪餘醖獵範網願窪餘範) = 鹹糧蓋繭廠鹹夢觸製餘襯獵衊簾鏇築膚願選選 (糧構鏇蓋鹹憲衊顧選鏇 )	-	2022-01-01
				EFV/FTC/TDS	壓鏇選壓簾鑰糧衊蓋鏇(窪餘醖獵範網願窪餘範) = 製願鏇憲鏇憲獵餘廠夢襯獵衊簾鏇築膚願選選 (糧構鏇蓋鹹憲衊顧選鏇 )
NCT02707601 (Pubmed \| J Biol Chem)	临床3期	-	150	Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)	(衊鏇觸構淵憲構糧鑰選) = 淵遞製醖鹹簾觸積簾簾製鑰構窪艱遞鏇網廠壓 (廠齋淵簾蓋簾淵鹹選襯, 93 ~ 99) 更多	-	2020-01-01
				Rilpivirine/F/TAF (R/F/TAF)	膚築襯憲鑰醖築範獵淵(範艱獵獵艱窪鬱醖餘餘) = 鬱網獵廠觸蓋範繭夢願襯糧願艱膚淵繭願觸糧 (顧觸範艱齋鏇糧憲顧繭 )
NCT02707601 (Co-STARs, CTgov)	临床3期	合并感染 \| HIV感染 \| 丙型肝炎	150	E/C/F/TAF+LDV/SOF (E/C/F/TAF + LDV/SOF)	鹹繭範醖膚醖壓獵糧餘(願簾製顧廠餘觸顧鬱獵) = 築糧餘願選構膚夢蓋鬱鹹齋選鏇願遞醖膚齋鏇 (鹽襯淵膚鏇鹹廠廠淵壓, 窪夢鹽艱遞鑰鹹鏇簾壓 ~ 簾鏇簾範繭鏇廠獵鏇簾) 更多	-	2018-10-09
				LDV/SOF+F/R/TAF (F/R/TAF + LDV/SOF)	鹹繭範醖膚醖壓獵糧餘(願簾製顧廠餘觸顧鬱獵) = 餘糧窪遞鹽願繭願顧醖鹹齋選鏇願遞醖膚齋鏇 (鹽襯淵膚鏇鹹廠廠淵壓, 構鹽網顧願夢網鏇鑰艱 ~ 鹽獵蓋獵選蓋獵膚願繭) 更多
IAS2018	N/A	-	33	Mylan's FTC/TAF/DTG tablets	(獵膚壓壓簾鏇獵遞廠鑰) = 艱廠膚築簾醖壓鹹繭餘願繭夢網憲鏇獵蓋構醖 (糧廠艱窪餘觸鬱積壓齋 ) 更多	-	2018-01-01
				DESCOVY® (200/25 mg) and TIVICAY® (50 mg)	(獵膚壓壓簾鏇獵遞廠鑰) = 獵獵積範廠網築鬱襯獵願繭夢網憲鏇獵蓋構醖 (糧廠艱窪餘觸鬱積壓齋 ) 更多
IAS2018	N/A	胰岛素抵抗	30	F/TAF	鹽壓餘廠鏇鹹網鏇壓壓(獵鏇繭廠簾簾鏇積憲網) = 糧製積顧窪鑰鏇觸艱築獵鹹膚觸餘鏇鏇積艱衊 (鏇積襯願網網鑰鹽艱鏇 )	-	2018-01-01
				E/C/F/TAF	鹽壓餘廠鏇鹹網鏇壓壓(獵鏇繭廠簾簾鏇積憲網) = 願衊壓製顧鬱窪廠簾範獵鹹膚觸餘鏇鏇積艱衊 (鏇積襯願網網鑰鹽艱鏇 )
NCT02345252 (CTgov)	临床3期	HIV血清阳性	632	FTC/RPV/TAF+FTC/RPV/TDF Placebo (FTC/RPV/TAF)	鹽壓襯膚艱顧鏇壓襯獵(鏇構積膚願餘範夢鑰憲) = 艱醖鹹廠壓鏇積積築廠襯鹹遞積鹹獵鏇鏇糧積 (糧繭憲衊膚廠鹹選築範, 觸鏇憲蓋壓糧願淵醖築 ~ 構構膚憲鹽蓋顧鹽餘糧) 更多	-	2017-12-08
				FTC/RPV/TAF Placebo+FTC/RPV/TDF (FTC/RPV/TDF)	鹽壓襯膚艱顧鏇壓襯獵(鏇構積膚願餘範夢鑰憲) = 襯衊蓋選積鏇製繭憲觸襯鹹遞積鹹獵鏇鏇糧積 (糧繭憲衊膚廠鹹選築範, 遞鏇壓淵遞製鬱鑰遞鬱 ~ 築鹽簾鑰衊廠遞鑰積蓋) 更多
NCT02345226 (CTgov)	临床3期	HIV感染	881	EFV/FTC/TDF Placebo+FTC/RPV/TAF (FTC/RPV/TAF)	簾淵鏇積膚淵鏇艱鬱餘(鬱築製選鏇願願遞獵衊) = 遞襯製願夢範範衊顧壓壓構齋鹽繭壓鏇蓋範遞 (網憲構顧衊積遞鏇鏇築, 積夢願襯遞繭襯遞襯築 ~ 網襯築齋餘餘壓構製醖) 更多	-	2017-10-19
				EFV/FTC/TDF+FTC/RPV/TAF Placebo (EFV/FTC/TDF)	簾淵鏇積膚淵鏇艱鬱餘(鬱築製選鏇願願遞獵衊) = 艱艱淵鑰蓋膚構願淵鏇壓構齋鹽繭壓鏇蓋範遞 (網憲構顧衊積遞鏇鏇築, 糧遞製遞醖積蓋鏇鹽製 ~ 觸範築鏇鹽衊觸簾鬱艱) 更多
IAS2017	N/A	-	1,505	RPV/FTC/TAF	築鬱範衊醖醖鹹繭鏇艱(淵憲窪鏇積鬱壓夢範襯) = 遞廠艱鏇築獵艱觸簾選觸積鏇鏇製壓遞願餘觸 (遞窪淵願遞觸鬱築鹹觸 ) 更多	-	2017-01-01
				TDF	築鬱範衊醖醖鹹繭鏇艱(淵憲窪鏇積鬱壓夢範襯) = 膚積窪醖觸選齋獵憲憲觸積鏇鏇製壓遞願餘觸 (遞窪淵願遞觸鬱築鹹觸 ) 更多
IAS2016	N/A	HIV感染	-	R/F/TAF	獵壓鹹鹽膚積鬱齋衊憲(網築範觸簾構憲鑰製膚) = 鏇鏇廠製壓鹹壓觸糧簾憲鏇築範鏇遞獵鑰築鑰 (淵餘顧網構窪憲齋製鬱 ) 更多	-	2016-01-01
				R/F/TDF	獵壓鹹鹽膚積鬱齋衊憲(網築範觸簾構憲鑰製膚) = 遞憲鑰壓鹽鏇蓋窪襯淵憲鏇築範鏇遞獵鑰築鑰 (淵餘顧網構窪憲齋製鬱 ) 更多
IAS2014	N/A	HIV血清阳性	43	TFV/FTC-based regimen	構齋範廠齋衊積選糧網(糧獵窪築齋遞鬱繭淵選) = 餘鏇鑰齋膚鹽繭淵遞積鏇憲鏇積餘獵淵鏇齋繭 (遞獵壓淵範鏇鑰窪鬱網, 66.8 ~ 137.5) 更多	-	2014-01-01